X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Kolinpharma will use its existing sales network and relationships with relevant clinical communities to market Iron Hydroxide Adipate Tartrate (IHAT), an oral iron supplementation product for iron deficiency, under its brand KIPFeR.
Lead Product(s): Iron Hydroxide Adipate Tartrate
Therapeutic Area: Hematology Product Name: KIPFeR
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Kolinpharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 10, 2024
Details:
The net proceeds will fund the completion of research & development to Market Authorization of Nemysis' novel E40 (endoprotease 40 glutenase) for the prevention of symptomatic gluten exposure in gluten intolerance and sensitivity.
Lead Product(s): Endoprotease 40 Glutenase
Therapeutic Area: Gastroenterology Product Name: E40
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: European Union
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Funding November 07, 2023
Details:
Under the agreement, Bruno will use its existing sales network and relationships with relevant clinical communities to market IHAT (iron hydroxide adipate tartrate), an oral iron supplementation product, under its own brand.
Lead Product(s): Iron Hydroxide Adipate Tartrate
Therapeutic Area: Hematology Product Name: IHAT
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bruno Farmaceutici
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 05, 2023
Details:
The patent claims describe methods for producing IHAT (Iron Hydroxide Adipate Tartrate), where Generally Recognised As Safe (GRAS) organic acids, and particularly Tartaric and Adipic acids, are used to modify the ferrihydrite nanocore of ferritin.
Lead Product(s): Iron Hydroxide Adipate Tartrate
Therapeutic Area: Hematology Product Name: IHAT-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
